Patent US5126325A successfully refreshed from Google Patents.
US5126325A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating thrombocytopenia
Assignee: Ajinomoto Co Inc
•
Filing: 1990-01-10
•
Granted: 1992-06-30
•
Expires: 2010-01-10
Abstract
Abstract Thrombocytopenia is treated by administering to a subject a therapeutic amount of human B cell differentiation factor or its biological equivalent.
Inventors
- 👤 Tadamitsu Kishimoto
- 👤 Toshio Hirano
- 👤 Hideo Kimura
- 👤 Toshiyuki Ishibashi
- 👤 Yukio Akiyama
- 👤 Akira Okano
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 14:42
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/204; A61P; A61P7/00; A61P7/04
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
24 words
A method for treating thrombocytopenia, comprising: treating a subject suffering from thrombocytopenia with a composition containing a substance having human B cell differentiation activity.
Claim 2
Independent Claim
24 words
A method for treating thrombocytopenia, comprising: treating a subject suffering from thrombocytopenia with a composition containing a substance having human B cell differentiation activity.
Claim 3
Dependent Claim
212 words
The method of claim 1, wherein said substance having human B cell differentiation activity is human BCDF which has the amino acid sequence (I) as follows: __________________________________________________________________________
Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val
Ala Ala Pro His Arg Gln Pro Leu Thr Ser Ser
Glu Arg Ile Asp Lys Gln Ile Arg Tyr Ile Leu
Asp Gly Ile Ser Ala Leu Arg Lys Glu Thr Cys
Asn Lys Ser Asn Met Cys Glu Ser Ser Lys Glu
Ala Leu Ala Glu Asn Asn Leu Asn Leu Pro Lys
Met Ala Glu Lys Asp Gly Cys Phe Gln Ser Gly
Phe Asn Glu Glu Thr Cys Leu Val Lys Ile Ile
Thr Gly Leu Leu Glu Phe Glu Val Tyr Leu Glu
Tyr Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu
Gln Ala Arg Ala Val Gln Met Ser Thr Lys Val
Leu Ile Gln Phe Leu Gln Lys Lys Ala Lys Asn
Leu Asp Ala Ile Thr Thr Pro Asp Pro Thr Thr
Asn Ala Ser Leu Leu Thr Lys Leu Gln Ala Gln
Asn Gln Trp Leu Gln Asp Met Thr Thr His Leu
Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser
Ser Leu Arg Ala Leu Arg Gln Met.
__________________________________________________________________________
Claim 4
Dependent Claim
213 words
The method of claim 1, wherein said substance having human B cell differentiation activity is human BCDF which has the amino acid sequence (II) as follows: __________________________________________________________________________
Ala Pro Val Pro Pro Gly Glu Asp Ser Lys Asp
Val Ala Ala Pro His Arg Gln Pro Leu Thr Ser
Ser Glu Arg Ile Asp Lys Gln Ile Arg Tyr Ile
Leu Asp Gly Ile Ser Ala Leu Arg Lys Glu Thr
Cys Asn Lys Ser Asn Met Cys Glu Ser Ser Lys
Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu Pro
Lys Met Ala Glu Lys Asp Gly Cys Phe Gln Ser
Gly Phe Asn Glu Glu Thr Cys Leu Val Lys Ile
Ile Thr Gly Leu Leu Glu Phe Glu Val Thr Leu
Glu Tyr Leu Gln Asn Arg Phe Glu Ser Ser Glu
Glu Gln Ala Arg Ala Val Gln Met Ser Thr Lys
Val Leu Ile Gln Phe Leu Gln Lys Lys Ala Lys
Asn Leu Asp Ala Ile Thr Thr Pro Asp Pro Thr
Thr Asn Ala Ser Leu Leu Thr Lys Leu Gln Ala
Gln Asn Gln Trp Leu Gln Asp Met Thr Thr His
Leu Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln
Ser Ser Leu Arg Ala Leu Arg Gln Met.
__________________________________________________________________________
Claim 5
Dependent Claim
24 words
The method of claim 1 or 2, wherein said substance having human B cell differentiation activity is human BCDF which has no sugar chain.
Claim 6
Dependent Claim
29 words
The method of claim 1, 2, or 3, wherein said substance having human B cell differentiation activity is human B cell differentiation factor which is produced in a prokaryote.
Claim 7
Independent Claim
35 words
A method for treating thrombocytopenia, comprising: treating a subject suffering from thrombocytopenia with a composition containing a substance having human B-cell differentiation activity as its principal active ingredient in combination with a pharmaceutically acceptable excipient.
Claim 8
Independent Claim
35 words
A method for treating thrombocytopenia, comprising: treating a subject suffering from thrombocytopenia with a composition containing a substance having human B-cell differentiation activity as its principal active ingredient in combination with a pharmaceutically acceptable excipient.
Claim 9
Independent Claim
22 words
A method for treating thrombocytopenia, comprising: treating a subject suffering from thrombocytopenia with human B cell differentiation factor sugar chains attached thereto.
Claim 10
Independent Claim
22 words
A method for treating thrombocytopenia, comprising: treating a subject suffering from thrombocytopenia with human B cell differentiation factor sugar chains attached thereto.
Claim 11
Dependent Claim
25 words
The method of claim 4, wherein said substance having human B cell differentiation activity is human B cell differentiation factor which is produced in prokaryote.
References Cited (Backward Citations)
WO1988000206A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-06-30 | 1995-12-30 | 1996-06-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-06-30 | 1999-12-30 | 2000-06-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-06-30 | 2003-12-30 | 2004-06-30 | $7700.00 | Window Closed / Lapsed |